Ajanta Pharma Ltd
Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).
- Market Cap ₹ 26,946 Cr.
- Current Price ₹ 2,140
- High / Low ₹ 2,355 / 1,241
- Stock P/E 35.4
- Book Value ₹ 267
- Dividend Yield 1.68 %
- ROCE 21.3 %
- ROE 17.0 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
- Company's working capital requirements have reduced from 129 days to 92.4 days
Cons
- Stock is trading at 8.03 times its book value
- Promoter holding has decreased over last 3 years: -4.13%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
599 | 839 | 1,110 | 1,356 | 1,574 | 1,804 | 1,825 | 1,773 | 2,196 | 2,719 | 3,141 | 3,411 | 3,894 | |
481 | 632 | 764 | 884 | 1,044 | 1,166 | 1,279 | 1,291 | 1,664 | 1,800 | 2,246 | 2,710 | 2,872 | |
Operating Profit | 118 | 207 | 346 | 473 | 529 | 638 | 547 | 481 | 533 | 919 | 895 | 701 | 1,022 |
OPM % | 20% | 25% | 31% | 35% | 34% | 35% | 30% | 27% | 24% | 34% | 28% | 21% | 26% |
6 | 7 | 18 | 27 | 80 | 63 | 73 | 102 | 180 | 102 | 136 | 131 | 134 | |
Interest | 14 | 18 | 8 | 5 | 4 | 1 | 0 | 0 | 9 | 7 | 9 | 5 | 7 |
Depreciation | 31 | 33 | 42 | 49 | 43 | 59 | 57 | 70 | 91 | 111 | 121 | 127 | 131 |
Profit before tax | 80 | 164 | 313 | 445 | 563 | 641 | 562 | 513 | 613 | 902 | 901 | 700 | 1,019 |
Tax % | 17% | 38% | 29% | 31% | 25% | 22% | 24% | 24% | 28% | 25% | 20% | 20% | |
66 | 101 | 221 | 306 | 422 | 500 | 428 | 392 | 441 | 676 | 720 | 559 | 762 | |
EPS in Rs | 5.04 | 7.66 | 16.76 | 23.21 | 31.97 | 37.86 | 32.39 | 29.93 | 33.70 | 52.05 | 56.20 | 43.61 | 60.34 |
Dividend Payout % | 13% | 15% | 16% | 17% | 17% | 23% | 0% | 20% | 26% | 12% | 11% | 16% |
Compounded Sales Growth | |
---|---|
10 Years: | 15% |
5 Years: | 13% |
3 Years: | 16% |
TTM: | 17% |
Compounded Profit Growth | |
---|---|
10 Years: | 18% |
5 Years: | 5% |
3 Years: | 7% |
TTM: | 32% |
Stock Price CAGR | |
---|---|
10 Years: | 23% |
5 Years: | 26% |
3 Years: | 21% |
1 Year: | 65% |
Return on Equity | |
---|---|
10 Years: | 25% |
5 Years: | 21% |
3 Years: | 22% |
Last Year: | 17% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 12 | 12 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 17 | 17 | 25 | 25 |
Reserves | 260 | 344 | 519 | 769 | 1,114 | 1,486 | 1,914 | 2,125 | 2,444 | 2,868 | 3,152 | 3,221 | 3,331 |
190 | 123 | 129 | 71 | 68 | 0 | 0 | 0 | 23 | 26 | 20 | 33 | 31 | |
155 | 196 | 215 | 229 | 214 | 245 | 360 | 379 | 564 | 621 | 591 | 1,025 | 662 | |
Total Liabilities | 617 | 675 | 880 | 1,086 | 1,414 | 1,749 | 2,292 | 2,522 | 3,049 | 3,532 | 3,780 | 4,305 | 4,049 |
237 | 263 | 261 | 271 | 433 | 573 | 1,037 | 1,162 | 1,449 | 1,519 | 1,492 | 1,484 | 1,473 | |
CWIP | 3 | 12 | 94 | 170 | 240 | 339 | 61 | 261 | 131 | 108 | 153 | 209 | 205 |
Investments | 17 | 19 | 79 | 77 | 94 | 199 | 201 | 83 | 86 | 157 | 165 | 553 | 256 |
361 | 381 | 446 | 568 | 647 | 638 | 993 | 1,015 | 1,383 | 1,748 | 1,970 | 2,058 | 2,115 | |
Total Assets | 617 | 675 | 880 | 1,086 | 1,414 | 1,749 | 2,292 | 2,522 | 3,049 | 3,532 | 3,780 | 4,305 | 4,049 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
39 | 206 | 190 | 263 | 277 | 537 | 219 | 312 | 301 | 467 | 542 | 736 | |
-50 | -98 | -176 | -146 | -139 | -340 | -201 | -137 | -116 | -163 | -66 | -501 | |
12 | -96 | -20 | -101 | -128 | -198 | -1 | -181 | -134 | -269 | -457 | -105 | |
Net Cash Flow | 0 | 11 | -6 | 16 | 9 | -1 | 18 | -6 | 51 | 35 | 19 | 130 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 76 | 59 | 58 | 65 | 81 | 68 | 86 | 87 | 122 | 105 | 121 | 105 |
Inventory Days | 272 | 175 | 156 | 147 | 167 | 149 | 290 | 386 | 240 | 317 | 278 | 248 |
Days Payable | 178 | 158 | 116 | 104 | 128 | 121 | 193 | 173 | 166 | 159 | 120 | 128 |
Cash Conversion Cycle | 171 | 75 | 98 | 108 | 121 | 96 | 183 | 300 | 195 | 264 | 279 | 225 |
Working Capital Days | 89 | 58 | 55 | 59 | 91 | 73 | 115 | 132 | 132 | 139 | 154 | 92 |
ROCE % | 22% | 39% | 56% | 60% | 55% | 48% | 33% | 25% | 27% | 34% | 30% | 21% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
2d - Schedule of Earnings Conference Call to be held on 2nd May 2024, post Board meeting.
- Board Meeting Intimation for Board Meeting Scheduled To Be Held On Thursday 2Nd May 2024 To Consider And Approve Audited Financial Results (Consolidated & Standalone) For The Quarter And Year Ended 31St March 2024. 22 Apr
-
Compliance With Reg. 40(10) Of The Listing Regulations - Compliance Certificate
18 Apr - PFA herewith Compliance Certificate under Regulation 40(10) of the SEBI (LODR) Regulations, 2015 from a PCS for the year ended 31st March 2024.
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 15 Apr
- Compliance Certificate - Regulation 7(3) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 For The Period Ended 31St March 2024. 15 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
Jan 2024TranscriptNotesPPT REC
-
Oct 2023TranscriptPPTREC
-
Jul 2023TranscriptPPTREC
-
May 2023TranscriptPPT
-
Feb 2023Transcript PPT
-
Aug 2022TranscriptPPT
-
Jan 2022TranscriptPPT
-
Oct 2021TranscriptPPT
-
Jul 2021TranscriptPPT
-
Apr 2021TranscriptPPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Jul 2019TranscriptNotesPPT
-
Apr 2019TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Oct 2018TranscriptNotesPPT
-
Jul 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
Jan 2018TranscriptNotesPPT
-
Oct 2017TranscriptNotesPPT
-
Aug 2017TranscriptNotesPPT
-
May 2017TranscriptNotesPPT
-
Jan 2017TranscriptNotesPPT
-
Oct 2016TranscriptNotesPPT
-
Aug 2016TranscriptNotesPPT
-
Apr 2016TranscriptNotesPPT
-
Feb 2016TranscriptNotesPPT
India - Branded Generic business (31% of FY23 revenues)[1]
- Focused on niche and first-to-market drugs in 4 therapeutic areas - cardiology, ophthalmology, dermatology, pain management[2]
- Has an MR strength of ~2800
- Launched 23 products in India in FY22 out of which 6 were first to market.[3] The total product basket comprises 500+ products with 50% being 1st to market[4]